{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T01:18:40Z","timestamp":1794619120755,"version":"4.9.1"},"reference-count":65,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surveyophthalmol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Survey of Ophthalmology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.survophthal.2021.03.004","type":"journal-article","created":{"date-parts":[[2021,3,21]],"date-time":"2021-03-21T11:07:53Z","timestamp":1616324873000},"page":"1009-1020","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Primary central nervous system lymphoma \u2013 ocular variant: an interdisciplinary review on management"],"prefix":"10.1016","volume":"66","author":[{"given":"Vishal","family":"Raval","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0464-3372","authenticated-orcid":false,"given":"Elaine","family":"Binkley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary E.","family":"Aronow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Valenzuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Peereboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9411-0320","authenticated-orcid":false,"given":"Arun D.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.survophthal.2021.03.004_bib0001","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1200\/JCO.2005.13.524","article-title":"Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma","volume":"23","author":"Abrey","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0002","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1200\/JCO.2006.08.2941","article-title":"Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model","volume":"24","author":"Abrey","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0003","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1111\/cas.13012","article-title":"High-dose methotrexate following intravitreal methotrexate administration in preventing central nervous system involvement of primary intraocular lymphoma","volume":"107","author":"Akiyama","year":"2016","journal-title":"Cancer Sci"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0004","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/IIO.0000000000000055","article-title":"Primary central nervous system lymphoma","volume":"55","author":"Aziz","year":"2015","journal-title":"Int Ophthalmol Clin"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0005","first-page":"711","article-title":"High-dose methotrexate for intraocular lymphoma","volume":"9","author":"Batchelor","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0006","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/ICB.0000000000000668","article-title":"Therapeutic vitrectomy as an adjunct treatment to systemic chemotherapy for intraocular lymphoma","volume":"14","author":"Bever","year":"2020","journal-title":"Retin Cases Brief Rep"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0007","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ajh.25350","article-title":"Role of systemic high-dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: a single center experience 1990-2018","volume":"94","author":"Castellino","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0008","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1634\/theoncologist.2011-0210","article-title":"Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium","volume":"16","author":"Chan","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0009","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/neuonc\/nov253","article-title":"Intensive chemoimmunotherapy and bilateral globe irradiation as initial therapy for primary intraocular lymphoma","volume":"18","author":"Cheah","year":"2016","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0010","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/09273948.2017.1421669","article-title":"Clinical features and treatment outcomes of vitreoretinal lymphoma according to its association with CNS lymphoma","volume":"26","author":"Cho","year":"2018","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0011","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/j.1442-9071.2008.01843.x","article-title":"Understanding intraocular lymphomas","volume":"36","author":"Coupland","year":"2008","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0012","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/APO.0000000000000274","article-title":"Clinical features predictive of survival in patients with vitreoretinal lymphoma: analysis of 70 patients at a single ocular oncology center","volume":"9","author":"Dalvin","year":"2020","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0013","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/ajh.25414","article-title":"Bilateral radiation therapy followed by methotrexate-based chemotherapy for primary vitreoretinal lymphoma","volume":"94","author":"de la Fuente","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0014","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.survophthal.2020.02.001","article-title":"Eye involvement in primary central nervous system lymphoma","volume":"65","author":"Farrall","year":"2020","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0015","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/bjh.14025","article-title":"How we diagnose and treat vitreoretinal lymphoma","volume":"173","author":"Fend","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0016","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/annonc\/mdf080","article-title":"Relevance of intraocular involvement in the management of primary central nervous system lymphomas","volume":"13","author":"Ferreri","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0017","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1200\/JCO.2003.09.139","article-title":"Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience","volume":"21","author":"Ferreri","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0018","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S2352-3026(16)00036-3","article-title":"Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial","volume":"3","author":"Ferreri","year":"2016","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.survophthal.2021.03.004_bib0019","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1182\/asheducation-2017.1.565","article-title":"Therapy of primary CNS lymphoma: role of intensity, radiation, and novel agents","volume":"2017","author":"Ferreri","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0020","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1136\/bjo.2007.127928","article-title":"Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience","volume":"92","author":"Frenkel","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0021","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/annonc\/mdz032","volume":"30","author":"Ghesquieres","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0022","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.anndiagpath.2018.09.014","article-title":"Aggressive B cell lymphomas in the 2017 revised WHO classification of tumors of hematopoietic and lymphoid tissues","volume":"38","author":"Grimm","year":"2019","journal-title":"Ann Diagn Pathol"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0023","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1093\/annonc\/mdm340","article-title":"Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report","volume":"18","author":"Grimm","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0024","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1212\/01.wnl.0000327672.04729.8c","article-title":"Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report","volume":"71","author":"Grimm","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0025","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/blood-2018-09-875732","article-title":"Phase 1b trial of an ibrutinib-based combination therapy in recurrent\/refractory CNS lymphoma","volume":"133","author":"Grommes","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.survophthal.2021.03.004_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1167\/tvst.1.3.1","article-title":"Efficacy and complications of intravitreal rituximab injection for treating primary vitreoretinal lymphoma","volume":"1","author":"Hashida","year":"2012","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0027","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00417-014-2584-8","article-title":"Association between ocular findings and preventive therapy with onset of central nervous system involvement in patients with primary vitreoretinal lymphoma","volume":"252","author":"Hashida","year":"2014","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0028","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1200\/JCO.1999.17.4.1326c","article-title":"Intraocular methotrexate level after high-dose intravenous infusion","volume":"17","author":"Henson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0029","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3171\/jns.1988.68.6.0835","article-title":"Primary central nervous system lymphoma","volume":"68","author":"Hochberg","year":"1988","journal-title":"J Neurosurg"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0030","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/sj.eye.6700378","article-title":"Intraocular lymphoma: a series of 14 patients with clinicopathological features and treatment outcomes","volume":"17","author":"Hoffman","year":"2003","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0031","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-2141.2004.05028.x","article-title":"Ocular presentation of primary central nervous system lymphoma: diagnosis and treatment","volume":"126","author":"Hormigo","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0032","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00417-005-0138-9","article-title":"Intraocular lymphoma 2000-2005: results of a retrospective multicentre trial","volume":"244","author":"Jahnke","year":"2006","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0033","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/bjh.14848","article-title":"Combined intravitreal methotrexate and immunochemotherapy followed by reduced-dose whole-brain radiotherapy for newly diagnosed B-cell primary intraocular lymphoma","volume":"179","author":"Kaburaki","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0034","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/bjh.15005","article-title":"Clinical features and outcomes of secondary intraocular lymphoma","volume":"183","author":"Karakawa","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0035","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1136\/bjophthalmol-2017-311574","article-title":"Combined treatment of primary vitreoretinal lymphomas significantly prolongs the time to first relapse","volume":"102","author":"Klimova","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0036","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00277-014-2212-z","article-title":"Prognostic impact of intraocular involvement in primary CNS lymphoma: experience from the G-PCNSL-SG1 trial","volume":"94","author":"Kreher","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0037","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/ceo.13668","article-title":"Intraocular chemotherapy for vitreoretinal lymphoma: a review","volume":"48","author":"Kvopka","year":"2020","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0038","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1136\/bjophthalmol-2013-304043","article-title":"Use of intravitreal rituximab for treatment of vitreoretinal lymphoma","volume":"98","author":"Larkin","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0039","doi-asserted-by":"crossref","first-page":"242","DOI":"10.5045\/br.2015.50.4.242","article-title":"Intraocular lymphoma in Korea: the Consortium for Improving Survival of Lymphoma (CISL) study","volume":"50","author":"Lee","year":"2015","journal-title":"Blood Res"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0040","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1001\/jamaophthalmol.2013.569","article-title":"Vitreoretinal lymphoma: a 20-year review of incidence, clinical and cytologic features, treatment, and outcomes","volume":"131","author":"Levasseur","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0041","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00277-015-2582-x","article-title":"Clinical outcomes of primary intraocular lymphoma patients treated with front-line systemic high-dose methotrexate and intravitreal methotrexate injection","volume":"95","author":"Ma","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0042","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.3109\/10428194.2013.769216","article-title":"Preliminary results of radiotherapy for primary intraocular non-Hodgkin lymphoma","volume":"54","author":"Mikami","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0043","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/09273940902957305","article-title":"Epidemiology and clinical features of intraocular lymphoma","volume":"17","author":"Mochizuki","year":"2009","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0044","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/j.ophtha.2016.03.043","article-title":"Primary oculocerebral lymphoma: MTX polychemotherapy alone on intraocular disease control","volume":"123","author":"Nguyen","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0045","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/nox158","article-title":"CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014","volume":"19","author":"Ostrom","year":"2017","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0046","doi-asserted-by":"crossref","first-page":"534","DOI":"10.3324\/haematol.2014.108472","article-title":"Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group","volume":"100","author":"Pulczynski","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0047","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40942-018-0120-4","article-title":"The diagnosis and treatment of primary vitreoretinal lymphoma: a review","volume":"4","author":"Pulido","year":"2018","journal-title":"Int J Retina Vitreous"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0048","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jamaophthalmol.2014.4755","article-title":"Treatment strategies in primary vitreoretinal lymphoma: a 17-center European collaborative study","volume":"133","author":"Riemens","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0049","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/brain\/71.1.1","article-title":"Microgliomatosis; a form of reticulosis affecting the brain","volume":"71","author":"Russell","year":"1948","journal-title":"Brain"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0050","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.survophthal.2013.12.001","article-title":"Primary intraocular lymphoma","volume":"59","author":"Sagoo","year":"2014","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0051","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1001\/jamaophthalmol.2013.334","article-title":"Vitreoretinal presentation of secondary large B-cell lymphoma in patients with systemic lymphoma","volume":"131","author":"Salomao","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0052","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0053","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/09273940801899764","article-title":"Intravitreal methotrexate resistance in a patient with primary intraocular lymphoma","volume":"16","author":"Sen","year":"2008","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0054","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/S0161-6420(02)01125-9","article-title":"Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement","volume":"109","author":"Smith","year":"2002","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0055","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1167\/tvst.8.1.9","article-title":"Proceedings of the association for research in vision and ophthalmology and champalimaud foundation ocular oncogenesis and oncology conference","volume":"8","author":"Smith","year":"2019","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0056","first-page":"503","article-title":"Recticulum cell sarcoma of the central nervous system","volume":"89","author":"Sorger","year":"1963","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0057","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1097\/IAE.0000000000002851","article-title":"The concept of minimal residual disease in the treatment and staging of vitreoretinal lymphoma","volume":"40","author":"Stacey","year":"2020","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0058","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1365-2141.2010.08321.x","article-title":"Treatment of isolated primary intraocular lymphoma with high-dose methotrexate-based chemotherapy and binocular radiation therapy: a single-institution experience","volume":"151","author":"Stefanovic","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0059","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1365-2141.2011.08938.x","article-title":"Treatment of primary intraocular lymphoma with rituximab, high dose methotrexate, procarbazine, and vincristine chemotherapy, reduced whole-brain radiotherapy, and local ocular therapy","volume":"157","author":"Taoka","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0060","doi-asserted-by":"crossref","first-page":"795","DOI":"10.3109\/10428194.2013.819576","article-title":"Primary intraocular lymphoma: treatment outcomes with ocular radiation therapy alone","volume":"55","author":"Teckie","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0061","doi-asserted-by":"crossref","first-page":"668","DOI":"10.4103\/0973-1482.140824","article-title":"Therapeutic vitrectomy for vitreal recurrence of intraocular lymphoma resistant to intravitreal methotrexate post systemic chemotherapy","volume":"11","author":"Venkatesh","year":"2015","journal-title":"J Cancer Res Ther"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0062","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.survophthal.2005.11.002","article-title":"Primary testicular and intraocular lymphomas: two case reports and a review of the literature","volume":"51","author":"Wallace","year":"2006","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0063","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/bjh.12938","article-title":"Progress in central nervous system lymphomas","volume":"166","author":"Wang","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0064","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12886-020-01464-3","article-title":"Reduced frequency of Intravitreal methotrexate injection lowers the risk of Keratopathy in Vitreoretinal lymphoma patients","volume":"20","author":"Zhou","year":"2020","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.survophthal.2021.03.004_bib0065","first-page":"397","article-title":"Intraocular involvement is associated with a high risk of disease relapse in primary central nervous system lymphoma","volume":"41","author":"Zhuang","year":"2019","journal-title":"Oncol Rep"}],"container-title":["Survey of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625721000771?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625721000771?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T18:07:16Z","timestamp":1758737236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039625721000771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":65,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0039625721000771"],"URL":"https:\/\/doi.org\/10.1016\/j.survophthal.2021.03.004","relation":{},"ISSN":["0039-6257"],"issn-type":[{"value":"0039-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primary central nervous system lymphoma \u2013 ocular variant: an interdisciplinary review on management","name":"articletitle","label":"Article Title"},{"value":"Survey of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.survophthal.2021.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}